Vontobel Holding Ltd. reduced its position in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 44.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,800 shares of the company’s stock after selling 3,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in VanEck Pharmaceutical ETF were worth $361,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of PPH. Optimum Investment Advisors purchased a new stake in VanEck Pharmaceutical ETF during the 2nd quarter valued at about $27,000. GPS Wealth Strategies Group LLC purchased a new stake in VanEck Pharmaceutical ETF during the 2nd quarter valued at about $42,000. CWM LLC purchased a new stake in VanEck Pharmaceutical ETF during the 2nd quarter valued at about $55,000. International Assets Investment Management LLC purchased a new stake in VanEck Pharmaceutical ETF during the 2nd quarter valued at about $86,000. Finally, Comerica Bank boosted its holdings in VanEck Pharmaceutical ETF by 39.4% during the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock valued at $121,000 after acquiring an additional 378 shares during the period.
VanEck Pharmaceutical ETF Price Performance
PPH opened at $93.59 on Wednesday. The business has a 50 day simple moving average of $96.19 and a two-hundred day simple moving average of $92.51. The firm has a market capitalization of $719.71 million, a price-to-earnings ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a one year low of $74.05 and a one year high of $99.51.
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Recommended Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- CD Calculator: Certificate of Deposit Calculator
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What Are Dividend Achievers? An Introduction
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
